- Prospective product launches from Moderna outline an exciting future.
- Merck's pivotal achievements in hematology and oncology hold promising prospects.
- The ripple effects of these developments could potentially reshape the global healthcare delivery system.
- Economic impacts of these advancements can influence investment decisions in the healthcare sector.
The unfolding trajectories of pharmaceutical powerhouses Moderna and Merck are underpinned by intricate financial mechanisms, prominent among which is the capital asset pricing model (CAPM). In a nutshell, CAPM sheds light on the anticipated return on equity, dictated by the shared, non-diversifiable risk shouldered by the stakeholders of these companies. Moderna, for instance, with its strong lineup of innovative vaccines, emerges as a solid contender in the face of non-diversifiable market risk.
Setting this into context, we can draw a parallel with Novartis, an eminent Swiss pharmaceutical corporation that astounded the healthcare field with the introduction of Gleevec, a transformative drug for chronic myeloid leukemia, in 2000. Powered by this flagship drug, which contributed generously to annual revenue culminating in sales of $4.7 billion in 2014, Novartis saw its stock prices catapult 200% in 2003 in response to investors recognizing its potential.
Comments